Aflibercept shown to work at higher dose, longer intervals

Belmont Eye Center News

[ad_1] Regeneron Pharmaceuticals Inc. this week announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg (Eylea) with 12- and 16-week dosing regimens in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). The PHOTON trial in DME and the PULSAR trial in wAMD both demonstrated…

Read More
Scientists in lab - DNA Structure

Research focuses on retinal issues following COVID-19 infection

Belmont Eye Center News

[ad_1] Retinal involvement following a COVID-19 infection is rare but can happen after severe infections in immunocompetent individuals, according to Yusar Asad, MD, and colleagues from the Vitreoretinal Services, Centre for Sight, Delhi, India. The research team conducted a retrospective review of consecutive patients presenting with retinal manifestations attributable to COVID 19 between May 2020…

Read More
NYC Skyline

Moving past the eyes and into the brain

Belmont Eye Center News

[ad_1] Reviewed by Lotfi Merabet, OD, PhD, MPH, and Jessie Cronan Cortical/cerebral visual impairment (CVI), a condition related to brain injury, is visual impairment resulting from damage to the visual pathways in the brain. Unfortunately, CVI is all too common although not frequently diagnosed. And therein lies the problem. CVI is the leading cause of…

Read More
Close up of an eye

Screen and treat unstable tear film in weeks

Belmont Eye Center News

[ad_1] Patient expectations for cataract surgery are very high, especially when it comes to advanced-technology implants. To meet those expectations, we need accurate preoperative measurements as a basis for intraocular lens calculations, and we can’t have accurate measurements without a stable tear film. Objective tests such as tear osmolarity and matrix metalloproteinase 9 (MMP-9) offer…

Read More
Close up of an eye